Intra-Cellular Therapies Inc expected to post a loss of 59 cents a share - Earnings Preview

Intra-Cellular Therapies

27/02/2023 15:56

* Intra-Cellular Therapies Inc  ITCI.OQ   ITCI.O  is
expected
to show a rise in quarterly revenue when it reports  results on
March 1. 
    * The New York City-based  company is expected to report  a
238.8% increase in revenue to $86.971 million from $25.67
million a year ago, according to the mean estimate from 13
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Intra-Cellular
Therapies
Inc is for a loss of 59 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for
Intra-Cellular
Therapies Inc is $70​, above​ its last closing price of $47.32.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.82       -0.81      -0.57     Beat    30
 Jun. 30 2022  -0.73       -0.76      -0.92     Missed  -21
 Mar. 31 2022  -0.97       -0.92      -0.78     Beat    15.3​
 Dec. 31 2021  -0.99       -0.99      -1.05     Missed  -5.6
 ​​Sep.        -0.92       -0.92      -0.95     Missed  -3.3
 30 2021                                                
 Jun. 30 2021  -0.77       -0.79      -0.85     Missed  -7.4​
 Mar. 31 2021  -0.81       -0.80      -0.65     Beat    18.9
 Dec. 31 2020  -0.83       -0.85      -0.76     Beat    10.1
 This summary was machine generated February 27 at 15:56 GMT. 
All figures in US dollars  unless otherwise stated